An interventional study of HT-ENDO-MOS-A13 and Normal diagnosis in Hypertension, sponsored by JDeinum. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-30.
Sponsored by JDeinum · Not applicable, Interventional, and Diagnostic
Rationale: Diagnosis of endocrine forms of hypertension (primary aldosteronism, pheochromocytoma/paraganglioma and Cushing syndrome) is a lengthy and tedious process. Recently a multiomics biomarker was developed through machine learning that shows high accuracy in predicting the presence of endocrine hypertension or primary hypertension. Given the propensity to data shift in applications of machine learning derived algorithms validation of this multiomics biomarker in a prospective comparative trial is warranted.
Objective: To determine the diagnostic performance of the new diagnostic biomarker
Study design: A randomized, diagnostic, outcome-based trial
Study population: Hypertensive patients 18-75 yrs, referred to ESH Hypertension Excellence centers, who may suffer from endocrine hypertension.
Intervention (if applicable): One group is diagnosed by classic endocrine tests, the other by the multiomics biomarker. Ensuing treatment depends on diagnosis and subtyping results.
Main study parameters/endpoints:
Primary endpoint is potency of antihypertensive medication to reach a target systolic blood pressure value of 135 mm Hg by home blood pressure measurement or an equivalent value for ambulatory blood pressure measurement, standardized office blood pressure measurement or unattended automatic blood pressure measurement.
Secondary endpoints: Ambulatory blood pressure, biochemical cure of endocrine hypertension (if treated by surgery), costs, quality of life
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: In the control group patients follow the same diagnostic itinerary as in usual care. In the biomarker group, endocrine tests will have been replaced by a blood and urine collection. The risk in both arms consists of missing an endocrine diagnosis. From the preceding accuracy study this risk is low for the use of the biomarker. After 6 months follow-up patients that were diagnosed by the biomarker may switch to a classic analysis.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's planned enrollment of 250 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →This is the only study on the registry with JDeinum as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants in this arm will be diagnosed with the mutli-omics based biomarker
Diagnostic Test: HT-ENDO-MOS-A13
Other: Normal diagnosis
Mutli-Omics based biomarker to diagnose primary hypertension or endocrine forms of hypertension; primary aldosteronism, pheochromocytoma/functional paraganglioma or Cushing syndrome.
Standard diagnosis for endocrine hypertension
Potency of antihypertensive medication
Primary endpoint is potency of antihypertensive medication to reach a target systolic blood pressure value of 135 mm Hg by home blood pressure measurement or an equivalent value for ambulatory blood pressure measurement, standardized office blood pressure measurement or unattended automatic blood pressure measurement.
Time frame: from date of start of treament until end of study evaluation (6 months)
Ambulatory blood pressure
Ambulatory blood pressure decrease comparison of the two diagnostic methods
Time frame: from date of start of treament until end of study evaluation (6 months)
Biochemical cure of endocrine hypertension (if treated by surgery)
Comparison of effectiveness of biochemical cure of endocrine hypertension (if treated by surgery) As defined by normalisation of aldosterone and renin levels in case of adrenalectomy for aldosterne producing adenoma, normalization of (nor)metanephrine levels after surgery for pheochromocytoma, or normalization of cortisol levels after hypophysectomy or adrenalectomy in Cushing disease/syndrome.
Time frame: from date of start of treament until end of study evaluation (6 months)
Cost
Cost-effectiveness comparison between the two diagnostic methods.for a cost-effectiveness analysis we will use the costs of all procedures and the results of the EQ-5D questionnaire.
Time frame: from date of randomization until end of study evaluation (6 months)
Quality of life EQ-5D (min 00000- max 55555, with 55555 having the best quality of life)
Quality of life comparison between participants in the two arms using the EQ-5D
Time frame: from date of start of treament until end of study evaluation (6 months)
Quality of life SF-36 (36-Item Short Form Health Survey, 0-100 for each scale, lower means worse qulaity of life)
Quality of life comparison between participants in the two arms using the SF-36
Time frame: from date of start of treament until end of study evaluation (6 months)
Extra standard analysis
proportion of participants diagnosed with PHT in the intervention MOMICS-ENDO arm who choose to undergo a standard analysis after the end of follow-up
Time frame: From end of follow-up of trial to initial diagnosis confirmed or not (around 3 months)
EHT after secondary standard analysis
number of participants with PHT in the MOMICS-ENDO arm who have EHT after a secondary standard analysis after the end of follow-up.
Time frame: From end of follow-up of trial to initial diagnosis confirmed or not (around 3 months)
carbon footprints of both arms
comparison of the carbon footprints of both arms
Time frame: from inclusion to end of follow-up (6 months after start of treatment)
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.